Loading...
•
Jun 30, 2023
EyePoint Pharmaceuticals Q2 2023 Earnings Report
Announced financial results for the second quarter ended June 30, 2023 and highlighted recent corporate developments.
Key Takeaways
EyePoint Pharmaceuticals reported a decrease in total net revenue to $9.1 million compared to $11.6 million for the same quarter last year. The company sold the YUTIQ® franchise for $82.5 million cash plus future royalties, retired all outstanding bank debt, and extended their cash runway into 2025. They are focused on the clinical development of EYP-1901.
Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration remains on track to report topline data in December 2023.
Phase 2 PAVIA clinical trial evaluating EYP-1901 in non-proliferative diabetic retinopathy remains on track with topline data anticipated in 2Q 2024.
Jay S. Duker, M.D. was promoted to President and Chief Executive Officer.
YUTIQ® franchise was sold for $82.5 million cash plus future royalties; all outstanding bank debt was retired and cash runway extended into 2025.
Revenue by Segment
Forward Guidance
The company expects that the cash, cash equivalents and investments on June 30, 2023 will enable them to fund current and planned operations into 2025.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...